Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Don't let the high blood pressure that you have been diagnosed with scare you out of your wits. It is not exactly a disease, but only a warning sign that the food you have been eating and the lifestyle you have been leading have clogged your blood vessels and your heart is having to exert extra pressure to keep blood moving through it.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Paving the way for new depression treatments, researchers have discovered the first-ever connection between vulnerability to depression and a type of brain cells called noradrenergic neurons.

  • Substandard medicines could be three times more prevalent than the government says, two new studies show. These data have serious implications on health in a country where 58.2 percent of the total health expenditure is an out-of-pocket cost burden on people, according to the World Health Organization, and where medicines alone account for between 70 percent and 77 percent of health spending.

  • Optovue announced FDA clearance and immediate U.S. commercial availability of the AngioVue™ Imaging System, a groundbreaking technology that provides a non-invasive way to visualize abnormal blood vessels in the retina to help physicians determine an appropriate course of treatment.

  • Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

    Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region of Mindanao.

    The WCC partnership highlights Sandoz’s commitment to address key global healthcare challenges by pioneering new approaches to increase access to medicine.

    << Pharma News


    Subscribe to PharmaTutor News Alerts by Email >>

  • RedHill Biopharma Ltd, announced the successful completion of a first-in-man pharmacokinetic (PK) study of BEKINDA™ 12 mg formulation, intended to be administered in the Phase II study for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). RedHill further announced the submission to the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) protocol for the Phase II clinical study with BEKINDA™ 12 mg for IBS-D, planned to be initiated in the coming weeks, subject to final preparations.

Subscribe to Pharma News